Regeneron Pharmaceuticals, Inc. $REGN Stock Holdings Lowered by Lido Advisors LLC

Lido Advisors LLC cut its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 12.5% in the 1st quarter, Holdings Channel reports. The firm owned 11,739 shares of the biopharmaceutical company’s stock after selling 1,678 shares during the period. Lido Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $9,071,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in REGN. WPG Advisers LLC grew its position in Regeneron Pharmaceuticals by 312.5% in the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 25 shares during the last quarter. SHP Wealth Management acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $26,000. Titan Wealth CI Ltd acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $29,000. Kemnay Advisory Services Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth $31,000. Finally, Entrust Financial LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth $32,000. 83.31% of the stock is currently owned by institutional investors.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Analysts remain constructive ahead of Regeneron’s upcoming quarterly results, with one note saying the company is positioned to beat earnings expectations. Regeneron (REGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
• Positive Sentiment: Guggenheim raised its price target on Regeneron, signaling continued Wall Street confidence in the stock’s longer-term upside. Guggenheim Boosts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,000.00
• Neutral Sentiment: Multiple law firms are advertising deadlines and investor-rights notices related to the already-filed Regeneron securities class action, keeping the issue in the spotlight but not adding new allegations. The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit – REGN
• Neutral Sentiment: Additional firms, including Faruqi & Faruqi, Schall, and others, issued similar class-action reminders, which extends the legal-news flow around REGN. Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
• Negative Sentiment: Several lawsuits claim Regeneron misled investors about clinical-trial protocol and statistical risks, with one report citing a sharp selloff and an estimated $11 billion market-cap hit after the trial failure disclosure. Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial’s Protocol and Ultimate Failure – HBSS

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 200 shares of the company’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the transaction, the director owned 17,303 shares in the company, valued at $11,249,545.45. This represents a 1.14% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. Morgan Stanley cut their target price on Regeneron Pharmaceuticals from $788.00 to $730.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 8th. Canaccord Genuity Group dropped their price target on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Wall Street Zen downgraded Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. Wells Fargo & Company reduced their price objective on shares of Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating for the company in a research note on Monday, May 18th. Finally, Guggenheim raised their target price on shares of Regeneron Pharmaceuticals from $995.00 to $1,000.00 and gave the stock a “buy” rating in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $787.88.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $656.01 on Friday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $541.00 and a 1-year high of $821.11. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $69.35 billion, a price-to-earnings ratio of 15.98, a P/E/G ratio of 1.45 and a beta of 0.24. The stock’s fifty day simple moving average is $635.78 and its 200-day simple moving average is $714.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, beating the consensus estimate of $8.91 by $0.56. The firm had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.Regeneron Pharmaceuticals’s quarterly revenue was up 19.0% on a year-over-year basis. During the same period in the previous year, the firm earned $8.22 earnings per share. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.12 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th were issued a $0.94 dividend. The ex-dividend date was Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.16%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.